Vai ai contenuti. | Spostati sulla navigazione | Spostati sulla ricerca | Vai al menu | Contatti | Accessibilità

| Crea un account

Iaccarino, Luca (2007) Terapia di mantenimento della glomerulonefrite lupica con micofenolato mofetile: risultati di uno studio condotto su 70 pazienti. [Tesi di dottorato]

Full text disponibile come:

[img]Documento HTML
1122Kb
[img]
Anteprima
Documento PDF
1003Kb

Abstract (inglese)

Systemic lupus erithematosus (LES) is an autoimmune disease that can potentially involve any organ or system of the human body. Glomerulonephritis (GN) has been recognized as the most frequent severe manifestation of LES leading to poor long term prognosis. In the treatment of lupus GN, several therapeutic approaches, all including immunosuppressive drugs such as cyclophosphamide, azathioprine (AZA), or cyclosporine A (CYA) have been used. The short and long term toxicity of these drugs limits their use in a substantial number of patients. Mycophenolate mofetil (MMF) is an immunosuppressant which provides protection against transplant rejection. MMF has been more recently used in many autoimmune inflammatory conditions, including SLE. Over the last few years MMF has emerged as an alternative regimen mainly for patients with SLE manifestations refractory to other therapies. Since January 1999 we have treated 70 SLE patient with diffuse proliferative GN followed-up from three Northern Italian Rheumatological Centres: Padova, Brescia and Milano. In this 54-month, observational, prospective study 40 were treated with MMF and compared with 30 treated with standard therapy: AZA or CYA. This study has shown that MMF is highly effective and generally well tolerated.


Statistiche Download - Aggiungi a RefWorks
Tipo di EPrint:Tesi di dottorato
Relatore:Todesco, Silvano
Correlatore:Doria, Andrea
Dottorato (corsi e scuole):Ciclo 20 > Scuole per il 20simo ciclo > SCIENZE MEDICHE, CLINICHE E SPERIMENTALI > REUMATOLOGIA CLINICA E SPERIMENTALE
Data di deposito della tesi:2007
Anno di Pubblicazione:2007
Parole chiave (italiano / inglese):lupus eritematoso sistemico, micofenolato mofetile, glomerulonefrite,
Settori scientifico-disciplinari MIUR:Area 06 - Scienze mediche > MED/16 Reumatologia
Struttura di riferimento:Dipartimenti > Dipartimento di Scienze Mediche e Chirurgiche
Codice ID:599
Depositato il:09 Ott 2008
Simple Metadata
Full Metadata
EndNote Format

Bibliografia

I riferimenti della bibliografia possono essere cercati con Cerca la citazione di AIRE, copiando il titolo dell'articolo (o del libro) e la rivista (se presente) nei campi appositi di "Cerca la Citazione di AIRE".
Le url contenute in alcuni riferimenti sono raggiungibili cliccando sul link alla fine della citazione (Vai!) e tramite Google (Ricerca con Google). Il risultato dipende dalla formattazione della citazione.

1. Doria A, Iaccarino L, Ghirardello A et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006. 119: 700-6. Cerca con Google

2. ACR ad hoc Committee on SLE guideline. Arthritis Rheum 1999. 42: 1785-96. Cerca con Google

3. Todesco S, Doria A, Bernardi C, Ghirardello A, Corbanese S, Gianese G, Iaccarino L, Della Libera S, Gambari PF. Sopravvivenza, cause di morte e fattori prognostici nel LES: studio su una coorte di 338 pazienti seguiti in un unico centro reumatologico. Sem Clin Immunol 1999. 17: 73. Cerca con Google

4. Ghirardello A, Doria A, Gambari PF. Autoanticorpi ed autoantigeni nel lupus eritematoso sistemico. Studio mediante l'immunoblotting. Reumatismo1994. 46(4): 208-15. Cerca con Google

5. Rosen A, Casciola-Rosen L, Ahearn J. Novel packages of viral and self-antigens ara generated during apoptosis. J Exp Med 1995. 181: 1557-61. Cerca con Google

6. Utz PJ, Anderson P. Postranlational protein modification, apoptosis, and the bypass of tolerance to autoantigens. Artritis Rheum 1998. 41: 1152-60. Cerca con Google

7. Utz PJ, Hottelet M, Schur PH, Anderson P. Proteins phosphorilated during stress-induced apoptosis are common targets for autoantibody production in patients with systemic lupus erythematosus. J Exp Med 1997. 185: 843-54. Cerca con Google

8. Perniok A, Wedeking K, Herrmann M, Specker C, Schneider M. Hight levels of circulating early apoptotic peripheral blood mononuclear cells in systemic lupus erythematosus. Lupus 1998. 7: 113-8. Cerca con Google

9. Hermann M, Voll RE, Zoller OM, Hagenhofer M, Ponner BB, Kalden JR. Impaired phagocitosis of apoptotic cell material by monocyte-derived macrophages from patients with systemic lupus erythematosus. Arthritis Rheum 1998. 41: 1241-50. Cerca con Google

10. Furnier G. Circulation of DNA and lupus nephritis. Kidney Int 1988. 33: 487-97. Cerca con Google

11. Madaio MP. The role of autoantibodies in the pathogenesis of lupus nephritis. Seminars in Nephrology 1999. 19: 48-56. Cerca con Google

12. Foster MH, Kelley VR. Lupus nephritis: uptdate on pathogenesis and disease mechanism. Seminars in Nephrology 1999. 19: 173-181. Cerca con Google

13. Ghirardello A, Doria A, Villalta D, Zampieri S, Tozzoli R, Gambari PF. Gli anticorpi antinucleosomi: nuovo marker sierologico di lupus eritematoso sistemico. Reumatismo 2000. 52: 242-248. Cerca con Google

14. Amoura Z, Chabre H, Bach J, Koutouzov S. Antinucleosome antibodies and systemic lupus erythematosus. Adv nephrol 1997. 26: 303-16. Cerca con Google

15. Schiedeke T, Stockli FW, Weber R, Suigiaki Y, Batsford SR, Voat A. Histones have hight affinity for the glomerular basement membrane. J Exp Med. 1989. 1879-94. Cerca con Google

16. Batsford SR. Cationic antigens as mediators of inflammation. Apmis 1991. 99: 1-9. Cerca con Google

17. Vogt A, Batsford S, Morioka T. Nephritogenic antibodies in lupus nephritis. Tohoku J Exp Med 1994. 45: 273-9. Cerca con Google

18. Kramers C, Hylkema MN, van Bruggen MCJ, van de Lagemaat R, Dijkman HBPM, Assmann KJM, Smeenk RJT, Berden JH. Anti-nucleosome antibodies complexed to nucleosomal antigens show anti-DNA reactivity and bind to rat glomerular basement menbrane in vivo. J Clin Invest 1994. 94: 568-577. Cerca con Google

19. van Bruggen MCJ, Walgreen B, Rijke TP, Tamboer W, Kramers C, Smeenk RJT, Monestier M, Fournie GJ, Berden JH. Antigens specificity of antinuclears antibodies complexed to nucleosomes determines glomerular basement membrane binding in vivo. Eur J Immunol 1997. 27: 1564-9. Cerca con Google

20. Amoura Z, Koutouzov S, Chabre H, Cacoub P, Amoura I, Musset L, Bach JF, Piette JC. Presence of antinucleosome autoantibodies in a resctricted set of connective tissue diseases. Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Artrhritis Rheum 2000. 43: 76-84. Cerca con Google

21. Doria A, Villalta D, Ghirardello A, Tozzoli R, Bizzaro N, Zampieri S, Gambari GF. Antinucleosome antibodies in SLE: A 2-year follow-up study of 101 patients. Arthritis Rheum 2000. 43: S244. Cerca con Google

22. Yanase K, Smith RM, Puccetti A, Jarret L, Madaio MP. Receptor-mediated cellular entry of nuclear localizing anti-DNA antibodies via myosin I. Clin Invest 1997. 100: 25-31. Cerca con Google

23. Mooskeker MS, Cheney RE. Unconventional myosins. Anu Rev Dev Biol 1995. 11: 633-75. Cerca con Google

24. Geli MI, Riezman H. Role of type 1 myosins in receptor mediated endocytosis in yeast. Science 1996. 272: 533-5. Cerca con Google

25. Oberhammer F, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE, Walker PR. Apoptotic death in epitelial cells: cleavage of DNA to 300 and/or 500 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO 1993. 12: 3679-84. Cerca con Google

26. Cohen GM, SunX-M, Snowden RT, Dinsdale D, Skilleter DN. Key morphologic features of apoptosis may occur in the absence of internucleosomal DNA fragmentation. Biochem J 1992. 286: 331-4. Cerca con Google

27. Peithsch M, Polzar B, Stephan H, Crompton T, MacDonald HR, Mannherz HG, Tschopp J. Characterization of endogenous deoxyribonuclease involved in nuclear DNA degradation during apoptosis. EMBO 1993. 12: 371-7. Cerca con Google

28. Kroemer G, Petit P, Zamzami N, Vayssiere JL, Mignotte B. The biochemistry of programmed cell death. FASEB 1995. 9: 1277-87. Cerca con Google

29. Steller H. Mechanisms and genes of cellular suicide. Science 1995. 267: 1445-9. Cerca con Google

30. Pasquariello A, Morriconi L, Paleologo G, Mosca M, Moneta I, Bombardieri S, Ossi E, Conte E, Antonello A, Gambari PF, Doria A. The prognostic relevance of immunohistological findings in renal biopsy in systemic lupus erythematosus. Clin Exp Rheumatol 1996. 14 (S16): 49. Cerca con Google

31. Grande JP, Balow JE. Renal biopsy in lupus nephritis. Lupus 1998. 7: 611-7. Cerca con Google

32. Iaccarino L, Doria A, Vescovi F, Ghirardello A, Gianese G, Della Libera S, Gambari PF. La glomerulonefrite lupica: studio su una casistica di 70 biopsie renali. Progressi in reumatologia 2000. 1: 9 (IV Congresso Italiano dei Reumatologi ospedalieri). Cerca con Google

33. Churg J, Bernstein J, Glassork RJ. Lupus nephritis. In: Renal disease: Classification and atlas of glomerular disease, 2nd edn. Igaku-Shoin: New York, 1995. 151-179. Cerca con Google

34. Mc Cluskey R. Lupus nephritis: kidney pathology. New York: appleton-Century-Crofts, 1975. 456-59. Cerca con Google

35. Doria A, Iaccarino L, Ghirardello A, Vescovi F, Gianese G, Della Libera S, Gambari PF. La glomerulonefrite lupica. Progressi in Reumatologia 2000.1: 69-71. Cerca con Google

36. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in SLE. J Am Soc Nephrol 15: 241-250, 2004. Cerca con Google

37. Appel GB, Silva F, Pirani C, Meltzer J, Estes D. Renal involvment in systemic lupus erythematosus. Medicine 1978. 57: 371-410. Cerca con Google

38. Baldwin DS, Gluck MG, Lowenstein MJ, Gallo GR. Lupus nephritis: clinical causes as related to morphological forms and their transitions. Am J Med 1977. 62: 12-30. Cerca con Google

39. Banfi G, Mazzucco G, Dibelgoioso GB, Barbiano G, Bosiso M, Strata P, Confalonieri R, Ferrario F, Imbasciati E, Monga G. Morphological parameters in lupus nephritis: their relevance for classification and relationship with clinical and histological findings and outcome. Q J Med 1985. 217: 153-68. Cerca con Google

40. Hect B, Siegel N, Adler M, Kashgarian M, Hayslett JP. Prognostic indices in lupus nephritis. Medicine 1976. 55: 163-81. Cerca con Google

41. Appel GB, Valeri A. The course and the treatment of lupus nephritis. Annu Rev Med 1994. 45: 525-537. Cerca con Google

42. Appel GB, Pirani CL, D'Agati V. Renal vascular complication af systemic lupus erythematosus (editorial). J Am Soc Nephrol 1994. 4:1499-515. Cerca con Google

43. Morel-Maroger L, Mery JP, Droz D, Godin M, Verroust P, Koorilsky O, Richet G. The course of lupus nephritis: contribution of serial renal biopsies. Adv nephrol 1976. 6: 79-118. Cerca con Google

44. Farrugia E, Torres VE, Gastineau D, Michet CJ, Holley KE. Lupus anticoaugulant in systemic lupus erythematosus: a clinical and renal pathological study. Am Kidney Dis 1992. 20: 463-71. Cerca con Google

45. Frampton G, Perry GJ, Chan TM, Cameron JS. Significance of anticardiolipin and antiendothelial cell antibodies in the nephritis of lupus. Contribut Nephrol 1992. 99: 7-16. Cerca con Google

46. Frampton G, Hicks J, Cameron JS. Significance of antipfospholipid antibodies in patients with lupus nephritis. Kidney Int 1991. 39: 1225-31. Cerca con Google

47. Hugson MD, Nadasdy T, McCarty GA, Sholer C, Min KW, Silva F. Renal thrombotic microangiopathy in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Kidney Dis 1992. 20: 150-86. Cerca con Google

48. Asherson R, MacKorth-Young C, Harris E, Gharavi A, Huges G. Multiple venous and arterial thrombosis associated with the lupus anticoagulant and antibodies to cardiolipin in the absence of SLE. Rheumatol Int 1985. 5: 91. Cerca con Google

49. Yamamoto T, Nagase M, Hishida A, Honda N. Interstitial inflammatory and chronic tubulointerstitial lesions in lupus nephritis: comparison with thouse in IgA nephropaty. Lupus 1993. 2: 261-8. Cerca con Google

50. Hill GS, Delahousse M, Nocy D, Tomkiewicz E, Rémy P, Mignon F, Méry JP. A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int 2000. 58: 1160-73. Cerca con Google

51. Doria A, Piccoli A, Vesco P, Vaccaro E, de Zambiasi P, Cozzi L, Gambari PF. Outcome in Systemic lupus erythematosus. Lupus 1993. 2: 408. Cerca con Google

52. Doria A, Iaccarino L, Corbanese S, et al. La glomerulonefrite lupica: nuove acquisizioni su patogenesi, diagnosi e trattamento. Progressi in Reumatologia 2001. 2: 12-26. Cerca con Google

53. Doria A, Gambari PF, Todesco S. Therapy of lupus nephritis: the main challenge in the management of severe systemic lupus erythematosus. in: K.A. Boki, A.A. Drosos, H.M. Moutsopoulos, A.G. Tzioufas, P.G Vlachoyiannopoulos. VII Mediterranean Congress of Rheumatology. Monduzzi ed., Bologna 1994. 157-62. Cerca con Google

54. Austin HA III, Balow JE. Treatment of lupus nephritis. Seminars in Nephrology 2000. 20: 265-76. Cerca con Google

55. Chan TM, Li F-K, Hao WK, Chan KW, Lui SL, Tang S, Lai KN. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 1999. 8: 545-51. Cerca con Google

56. Gordon C, Dostal C, Petera P, et al. EULAR trial of pulse cycolphosphamide followed by azathioprine in lupus nephritis. Arthritis Rheum 1999. 42:S167. Cerca con Google

57. Chan TM, Li F-K, Hao WK, Chan KW, Lui SL, Tang S, Lai KN. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus 1999. 8: 545-51. Cerca con Google

58. Moroni G, Maccario M, Banfi G, Quaglini S, Ponticelli C. Treatment of menbranous lupus nephritis. Am J Kidney Dis 1998. 31: 681-6. Cerca con Google

59. Hallegua D, Wallace DJ, Metzger AL, Rinaldi RZ, Klinenberg JR. Cyclosporine for lupus menbranous nephritis: experience with ten patients and rewiew of the literature. Lupus 2000. 9: 241-51. Cerca con Google

60. Korbert SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J, Rohde RD. Factors predictive of outcome in severe lupus nephritis. Am J Kidney Dis 2000. 35: 904-14. Cerca con Google

61. Moroni G, Quaglini S, Maccario M, Banfi G, Ponticelli C. "Nephritis flares" are predictors of bad long-term renal outcome in lupus nephritis. Kind Int 1996. 50: 2047-2053. Cerca con Google

62. Ponticelli C, Moroni G. Flares in lupus nephritis: incidence, impact on renal survival and management. Lupus 1998. 7: 635-8. Cerca con Google

63. Gruppo italiano per lo studio della nefrite lupica (GISNEL): Lupus nephritis: prognostic factors and probability of maintaining life-supporting renal function 10 years after the diagnosis. Am J Kidney Dis 1992. 19: 473-479. Cerca con Google

64. Dubois EL, Wierzchowieski M, Cox MB et al: Duration and death in systemic lupus erythematosus: an analysis of 249 cases. JAMA 1974. 227: 1399. Cerca con Google

65. Ginzler EM, Felson DT, Anthony JM, Anderson JJ: Hypertension increases the risk of renal deterioration in Systemic Lupus Erythematosus. J Rheumatol 1993. 20: 1694-700. Cerca con Google

66. CLark WF, Moist LM. Management of chronic renal insufficiency in lupus nephritis: role of proteinuria, hypertension and dyslipidemia in the progression of renal disease. Lupus 1998. 7: 649-51. Cerca con Google

67. Kimberly RP, Lockshin MD, Sherman RL, Beary JF, Mouradian J, Cheigh JS. "End-stage" lupus nephritis: Clinical course to and outcome on dialysis. Experience with 39 patients. Am J Med 1981. 60: 277-87. Cerca con Google

68. Coplon NS, Diskin CJ, Petersen J, Swenson RS. The long-term clinical course of systemic lupus erythematosus in end stage renal disease. N Engl J Med 1983. 308: 186-90. Cerca con Google

69. Ward MM. Access to renal transplantation among patients with end-stage renal disease due to lupus nephritis. Am J Kid Dis 2000. 35: 915-22. Cerca con Google

70. Ward MM. Outcomes of renal transplantation among patients with end stage renal disease caused by lupus nephritis. Kidney International 2000. 57: 2136-43. Cerca con Google

71. Mojcik CF, Klippel JH. End stage renal disease and systemic lupus erythematosus. Am J Med 1996. 101: 100-7. Cerca con Google

72. BG.Katzung. Farmacologia generale e clinica. V edizione, Piccin Cerca con Google

73. G.Bonadonna, G.Robustelli della Cura, P. Valagussa. Medicina oncologica. VII edizione, Masson Cerca con Google

74. Boumpas DT, Austin HA III, Vaughn EM, Klippel JH, Steinberg AD, Yarboro CH, Balow JE. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992. 340: 741-5. Cerca con Google

75. Gourley MF, Austin HA, Scott D, Yarboro CH, Vaughan EM, Muir J, Boumpas DT, Klippel JH, Ballow JE, Steinberg AD. Methylprednisolone and Cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, A randomized, controlled trial. Ann Int Med 1996. 125: 549-57. Cerca con Google

76. Ciruelo E, de la Cruz L, Lopez I, Gomez-Reino JJ. Cumulative rate of relapse of lupus nephritis after successful treatment with cyclophosphamide. Arthritis Rheum 1996. 39: 2028-34. Cerca con Google

77. Ioannidis JP, Boki KA, Katsorida ME. Remission, relapse and remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int 2000. 57: 258-64. Cerca con Google

78. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int 1997. 51: 1188-95. Cerca con Google

79. BG.Katzung. Farmacologia generale e clinica. V edizione, Piccin Cerca con Google

80. G.Bonadonna, G.Robustelli della Cura, P. Valagussa. Medicina oncologica. VII edizione, Masson Cerca con Google

81. Tsokos GC. Immunomodulatory treatments in patients with rheumatic disease: mechanism of action. Semin Arthritis Rheum 1987. 17: 24-38. Cerca con Google

82. Satoshi M, Koyasu S. Mechanisms of action of cyclosporine. Immunopharmacol 2000. 47: 119-125. Cerca con Google

83. Su B, Jacinto E, Hibi M, Kallunki T, Karin M, Ben-Neriah Y. JNK is involved in signal integration during costimulation of T lynfocytes. Cell 1994. 77: 727-36. Cerca con Google

84. Emmi L. Chiarini F. Strategie immunosoppressive nelle malattie autoimmuni e nel trapianto d'organo. Rosini Ed. 2002. Pag. 73-120. Cerca con Google

85. G.Bonadonna, G.Robustelli della Cura, P. Valagussa. Medicina oncologica. VII edizione, Masso Cerca con Google

86. BG.Katzung. Farmacologia generale e clinica. V edizione, Piccin Cerca con Google

87. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000. 47: 85-118. Cerca con Google

88. Carr SF, E Papp, JC Wu and Y Natsumeda. Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993. 268: 27286-90. Cerca con Google

89. Glomsda BA, Blaheta RA, Hailer NP. Inhibition of monocyte/endothelial cell interactions and monocyte adhesion molecule expression by the immunosuppressant mycophenolate mofetil. Spinal Cord 2003. 41: 610-9. Cerca con Google

90. Cohn RG, Mirkovich A, Dunlap B, Burton P, Chiu SH, Eugui E, Caulfield JP. Mycophenolic acid increases apoptosis, lysosomes and lipid droplets in human lymphoid and monocytic cell lines. Transplantation 1999. 68: 411-8. Cerca con Google

91. Colic M, Stojic-Vukanic Z, Pavlovic B, Jandric D, Stefanoska I. Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clin Exp Immunol 2003. 134: 63-9. Cerca con Google

92. Lagaraine C, Lebranchu Y. Effects of immunosuppressive drugs on dendritic cells and tolerance induction. Transplantation 2003. 75 (S8): 37-42. Cerca con Google

93. Allison AC, Kowalski WJ, Muller CJ, Waters RV, Eugui EM. Mycophenolic acid and brequinar, inhibitors of purine and pyrimidine synthesis, block the glycosylation of adhesion molecules. Transplant Proc 1993. 25 (S2): 67-70. Cerca con Google

94. Senda M, DeLustro B, Eugui E, Natsumeda Y. Mycophenolic acid, an inhibitor of IMP dehydrogenase that is also an immunosuppressive agent, suppresses the cytokine-induced nitric oxide production in mouse and rat vascular endothelial cells. Transplantation 1995. 60: 1143-8. Cerca con Google

95. Shoenfeld Y, Gerli R, Doria A et al. Accelerated rated atherosclerosis in autoimmune rheumatic diseases. Circulation 2005. 112: 3337-3347 Cerca con Google

96. Haug C, Schmid-Kotsas A, Linder T, Jehle PM, Bachem MG, Gruenert A, Rozdzinski E. The immunosuppressive drug mycophenolic acid reduces endothelin-1 synthesis in endothelial cells and renal epithelial cells. Clinical Science 2002. 103 (S48): 76-80. Cerca con Google

97. Guo H, Leung JCK, Chan LYY, Lui SL, Tsang AWL, Lai KN. Modulation of intra-pulmonary TGF-? expression by mycophenolate mofetil in lupus prone MRL/lpr mice. Lupus 2005. 14: 583-592. Cerca con Google

98. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycphenolate mofetil. Clin Pharmacokinet 1998. 34: 429-455 Cerca con Google

99. Bullingham RE, Nicholls A, Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transpant Proc 1996. 28: 925-929. Cerca con Google

100. Warrens AN. The evolving role of mycophenolate mofetil in renal transplantation. Q J Med 2000. 93: 15-20. Cerca con Google

101. McMurray RW, Elbourne KB, Lagoo A, Lal S. Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus. J Rheumatol 1998. 25: 2364-2370. Cerca con Google

102. Ramos MA, Pinera C, Setien MA et al. Modulation of autoantibody production by mycophenolate mofetil: effects of the development of SLE in (NZB x NZW)F1 mice. Nephron Dial Transplant 2003. 18: 878-883. Cerca con Google

103. Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney 1998. 32: 318-322. Cerca con Google

104. Dooley MA, Cosio FG, Nachman PH et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999. 10: 833-839. Cerca con Google

105. Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999. 8: 731-6. Cerca con Google

106. Chan TM, Li FK, Tang CSO, Wong RWS, Fang GX, Ji YL, et al. Efficacy of mycophenolato mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med 2000. 343: 1156-62. Cerca con Google

107. Kingdon EJ, McLean AG, Psimenou E, Davenport A, Powis SH, Sweny P, Burns A. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001. 10: 606-11. Cerca con Google

108. Karim MY, Alba P, Cuadrado MJ, Abbs IC, D'Cruz DP, Khamashta MA, Hughes GR. Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology. 2002. 41: 876-82. Cerca con Google

109. Ginzler EM, Aranow C, Buyon J. A multicenter study of mycophenolate mophetil (MMF) vs. intravenous cyclophosphamide (CYC) as induction therapy for severe lupus nephritis (LN): preliminary results. Arthritis Rheum 2003. 48: S1690. Cerca con Google

110. Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM. Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology 2004. 43(3): 377-80. Cerca con Google

111. Contreras G, Pardo V, Leclercq B et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004. 350: 971-980. Cerca con Google

112. Ong LM, Hooi LS, Lim TO et al. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis. Nephrology 2005. 10: 504-510. Cerca con Google

113. Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long term study of mycophenolate mofetil as continuous induction and manteinance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005. 16: 1076-1084. Cerca con Google

114. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005. 353: 2219-2228. Cerca con Google

115. Goyal S, Nousari HC. Treatment of resistant discoid lupus erythematosus of the palms and soles with mycophenolate mofetil. J Am Acad Dermatol 2001. 45: 142-144. Cerca con Google

116. Pisoni CN, Sanchez FJ, Karim Y et al. Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 2005. 32: 1047-1052. Cerca con Google

117. Gaubitz M, Schorat A, Schotte H, Kern P, Domschke W. Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 1999. 8: 731-736. Cerca con Google

118. Vasoo S, Thumboo J, Fong KY. Refractory immune thrombocytopenia in systemic lupus erythmeatosus: response to mycophenolate mofetil. Lupus 2003. 12: 630-632. Cerca con Google

119. Chang HK. Successful treatment of refractory thrombocytopenia with mycophenolate mofetil in a patient with systemic lupus erythematosus. J Korean Med Sci 2005. 20: 883-885. Cerca con Google

120. Alba P, Karim MY, Hunt BJ. Mycophenolate mofetil as a treatment for autoimmune haemolytic anaemia in patients with systemic lupus erythematosus and antiphospholipid syndrome. Lupus 2003. 12: 633-635. Cerca con Google

121. Howard J, Hoffbrand AV, Prentice HG, Metha A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol 2002. 117: 712-715. Cerca con Google

122. Samad AS, Lindsley CB. Treatment of pulmonary hemorrage in childhood systemic lupus erythematosus with mycophenolate mofetil. South Med J 2003. 96:705-707. Cerca con Google

123. Shihab FS, Bennett WM, Yi H, Choi SO, Andoh TF. Mycophenolate mofetil ameliorates arteriolopathy and decreases transforming growth factor-beta1 in chronic cyclosporine nephrotoxicity. Am J Transplant 2003. 3: 1550-1559. Cerca con Google

124. Grisanti M, Nader A, Caciuttolo R. Central nervous system involvement due to systemic lupus erythematosus/antiphospholipid sindrome: successful treatment with mycophenolate mofetil. Lupus 2001. 10: S31 (abstract 76). Cerca con Google

125. Jose J, Paulose BK, Vasuki Z, Danda D. Mycophenolate mofetil in neuropsychiatric systemic lupus erythematosus. Indian J Med Sci 2005. 59: 353-356. Cerca con Google

126. Riskalla MM, Somers EC, Fatica RA, McCune WJ. Tolerability of mycophenalte mofetil in patients with systemic lupus erythematosus. J Rheumatol 2003. 30: 1508-1512. Cerca con Google

127. Opelz G, Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 2004. 4: 222-2230. Cerca con Google

128. Snanoudj R, Durrbach A, Leblond V et al. Primary brain lymphomas after kidney transplantation: presentation and outcome. Transplanatation 2003. 76: 930-937. Cerca con Google

129. Zandman-Goddard G, Shoenfeld Y. Infections and SLE. Autoimmunity 2005. 38: 473-485 Cerca con Google

130. Dasgupta N, Gelber AC, Racke F, Fine DM. Central nervous system lymphoma associated with mycophenolate mofetil in lupus nephritis. Lupus 2005. 14: 910-913. Cerca con Google

131. Bernatsky S, Ramsey-Goldman R, Rajan R et al. Non-Hodgkin's lymphoma in systemic lupus erythematosus. Ann Rheum Dis 2005. 64: 1507-1509. Cerca con Google

132. Gorgos L, Goldman D, Petri M. The ACR/SLICC damage index in systemic lupus erythematosus (SLE). Arthritis Rheum 1993. 36: S68. Cerca con Google

133. Bijl M, Horst G, Bootsma H, Limburg PC, Kallenberg CGM. Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk. Ann Rheum Dis 2003. 62: 534-9. Cerca con Google

134. Donadio GM JV, Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined cyclophosphamide. N Eng J Med 1978. 299: 1151-55. Cerca con Google

135. Moroni G, Doria A, Mosca M, Todesco S et al. A randomized pilot trial comparing cyclosporine and azathioprine for maintenance therapy in diffuse lupus nephritis over four years. Clin J Am Soc Nephrol. 1: 925-932, 2006. Cerca con Google

136. Tan EM, Cohn AS, Fries JF, Masi AT, McShane DJ, Rothfield NF. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982. 25: 1271. Cerca con Google

Download statistics

Solo per lo Staff dell Archivio: Modifica questo record